Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

Song, Kevin W., Mollee, Peter N., Hogge, Donna E., Gupta, Vikas, Bernett, Michael J., Forrest, Donna L., Lavoie, Julye C., Nevill, Thmas J., Nantel, Stephen H., Shepherd, John D., Smith, Clay A., Sutherland, Heather J., Toze, Cynthia L., Crump, Michael and Keating, Armand (2005) Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia and Lymphoma, 46 4: 525-531. doi:10.1080/10428190400025112


Author Song, Kevin W.
Mollee, Peter N.
Hogge, Donna E.
Gupta, Vikas
Bernett, Michael J.
Forrest, Donna L.
Lavoie, Julye C.
Nevill, Thmas J.
Nantel, Stephen H.
Shepherd, John D.
Smith, Clay A.
Sutherland, Heather J.
Toze, Cynthia L.
Crump, Michael
Keating, Armand
Title Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission
Journal name Leukemia and Lymphoma   Check publisher's open access policy
ISSN 1042-8194
1029-2403
Publication date 2005-04
Sub-type Article (original research)
DOI 10.1080/10428190400025112
Volume 46
Issue 4
Start page 525
End page 531
Total pages 7
Editor A. Polliack
J. Seymour
K. Van Besien
Place of publication London, United Kingdom
Publisher Informa Healthcare
Language eng
Subject 1103 Clinical Sciences
Formatted abstract
The impact of karyotype on the outcome of patients who undergo autotransplant for acute myeloid leukemia (AML) in second remission (CR2) has not been explored. We evaluated the outcomes of 40 patients who proceeded to autotransplant for AML in CR2 at 2 centers. The median age at autotransplant was 50 years (18 – 64 years) and the median duration of first remission was 15 months (0.8 – 51 months). High-dose therapy was melphalan 140 – 160 mg/m2 plus etoposide 60 mg/kg with or without total body irradiation (22), a busulfan-based regimen (17), and cyclophosphamide alone (1). Six patients (15%) died of treatment-related causes within the first 100 days. Event-free and overall survival at 3 years were both 38% (95% confidence interval 23 – 53%). At a median follow-up of 76 months (2 – 170) in surviving patients, 13 (32.5%) are alive and disease free. Graft purging did not significantly influence survival outcome (P= 0.94), although platelet engraftment was significantly delayed (P = 0.02). The relative risk of an event (relapse or death) for the karyotype risk groups was favorable 1.0; intermediate 4.2 (1.2 – 14.7); adverse 9.9 (1.5 – 63.9); unknown 2.3 (0.6 – 8.8) (P =0.028). We conclude that patients with AML in CR2 who undergo autotransplant can have durable remissions and those with a good risk karyotype are the most likely to obtain long-term disease-free survival.
Keyword Acute myeloid leukemia
Relapse
Autotransplant
Karyotype
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 12 Jan 2010, 12:12:07 EST by Simon Utteridge on behalf of Faculty Of Health Sciences